Mycoplasma Genitalium Infection, STI
Conditions
Keywords
chlamydia trachomatis, Mycoplasma Genitalium Infection, Neisseria gonorrhoeae, men who have sex with men, heterosexual men, people living with HIV
Brief summary
Worldwide, Mycoplasma genitalium (MG) is increasingly reported as an emerging cause of sexually transmitted infections. Internationally, the prevalence of MG is higher in male with urethritis and community groups especially among people living with HIV (PLHIV). While MG is treatable, antimicrobial resistance is a rising concern. This cross-sectional study aims to determine the prevalence of MG infection and the antimicrobial resistance pattern in HIV-infected male in Hong Kong. A total of 750 HIV-infected male attending HIV specialist clinic in Hong Kong would be recruited. The main outcome measures include prevalence of MG and resistance mutations to macrolide/fluoroquinolone in HIV-infected male; prevalence of MG/STI co-infections, as defined by concurrent detection of MG and one or more other bacterial STI.
Detailed description
A total of 750 HIV-infected male attending HIV specialist clinic in Hong Kong would be recruited. An online questionnaire would be self-administered. The participants would self-collect urine sample, rectal and pharyngeal swabs for MG, Chlamydia trachomatis (CT) and Neisseria Gonorrhoeae (NG) screening by nucleic acid amplification tests, and MG genotypic resistance mutations detection. Clinical data would be transcribed from medical records of recruited subjects.
Interventions
OTHERself-sampling kits for STI testing in the laboratory
Participants will receive the self-sampling kits and their submitted samples would be sent to laboratory for testing
Sponsors
Chinese University of Hong Kong
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* aged 18 or older, male, HIV-infected, and are attendees of the HIV specialist clinic, and can communicate in written and spoken English or Chinese
Exclusion criteria
* not able to provide consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| prevalence of MG infection | 1 year | detection of MG infections in self-collected samples divided by the total number of samples collected |
| prevalence of MG resistance mutations | 1 year | * detection of MG resistance mutations macrolide/fluoroquinolone in MG positive samples divided by the total number of MG positive samples * detection of MG resistance mutations macrolide/fluoroquinolone in MG positive samples divided by the total number of samples collected |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| prevalence of CT infection | 1 year | detection of CT infections in self-collected samples divided by the total number of samples collected |
| prevalence of NG infection | 1 year | detection of NG infections in self-collected samples divided by the total number of samples collected |
| prevalence of syphilis | 1 year | total number of reported syphilis diagnosis divided by total number of participants tested for syphilis in the clinic |
| prevalence of HCV infection | 1 year | total number of reported HCV diagnosis divided by total number of participants tested for HCV in the clinic |
| prevalence of overall STI | 1 year | total number of reported STI diagnosis divided by total number of participants tested for STI in the clinic |
Countries
Hong Kong
Outcome results
None listed